EcoDrugPlus

Bcl2 Like 2

Ensembl ID : ENSCHOG00000004794
Gene Symbol: BCL2L2
1 Cross references
64 Possible Orthologues:

Bcl2 Related Protein A1

Ensembl ID : ENSCHOG00000013107
Gene Symbol: BCL2A1
1 Cross references
133 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSCHOG00000001793
Gene Symbol: CCR4
1 Cross references
113 Possible Orthologues:

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSCHOG00000011496
Gene Symbol: CCR5
1 Cross references
152 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSCHOG00000003236
Gene Symbol: CCR9
1 Cross references
265 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSCHOG00000003050
Gene Symbol: CXCL8
1 Cross references
179 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSCHOG00000002361
Gene Symbol: CXCR4
1 Cross references
218 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSCHOG00000006326
Gene Symbol: CFTR
1 Cross references
217 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSCHOG00000000871
Gene Symbol: TOP1
1 Cross references
273 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSCHOG00000000458
Gene Symbol: TOP2A
1 Cross references
206 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSCHOG00000000694
Gene Symbol: TOP2B
1 Cross references
210 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSCHOG00000012294
Gene Symbol: EML4
1 Cross references
214 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).